hpbmcs

Robinin (NSC-9222) belongs to natural products, serving as a TLR2 inhibitor with cell permeability. Robinin exerts anti-inflammatory and antitumor activities through inhibiting the TLR2-PI3K-AKT pathway, and can be used for experimental research related to pancreatic cancer.

LRRK2-IN-3 is a potent, selective, orally active LRRK2 inhibitor that crosses the blood-brain barrier with an IC50 value of 0.6 nM in hPBMCs. LRRK2-IN-3 can be used to study Parkinson's disease.

Compound 17b, a TLR7 agonist also known as TLR7 agonist 14, exhibits high potency with an EC50 of 18 nM. It effectively activates mouse macrophages and human peripheral blood mononuclear cells (hPBMCs) at low-nanomolar concentrations [1].

TLR7 agonist 15 (compound 16b) is a potent activator of mouse macrophages and hPBMCs, with an EC50 of 18 nM, inducing robust responses at low-nanomolar concentrations [1].

TLR7 agonist 16 (compound 16d) is a potent activator of TLR7 with an EC50 value of 18 nM, effectively triggering the activation of mouse macrophages and human peripheral blood mononuclear cells (hPBMCs) at low-nanomolar levels [1].

E104 (compound 1), a selective TLR7 agonist, exhibits potent anticancer activity when delivered via antibody-drug conjugate (ADC) technology. It effectively activates mouse macrophages and human peripheral blood mononuclear cells (hPBMCs) [1].